Journal
NEURODEGENERATIVE DISEASE MANAGEMENT
Volume 3, Issue 2, Pages 147-155Publisher
FUTURE MEDICINE LTD
DOI: 10.2217/NMT.13.10
Keywords
-
Categories
Funding
- National Institute on Aging [P50 AG 16570]
- Alzheimer's Disease Research Centers of California
- Sidell-Kagan Foundation
- National Institute on Ageing, American Federation for Aging Research [K08 AG 34628]
- John A Hartford Foundation
- Atlantic Philanthropies
- Starr Foundation
Ask authors/readers for more resources
The updated diagnostic criteria for Alzheimer's disease (AD) distinguish three stages: dementia, symptomatic predementia (i.e., mild cognitive impairment) and asymptomatic predementia. Although AD is primarily associated with cognitive deficits, comorbid depressive symptoms frequently occur at each stage. Depression in AD dementia is qualitatively different from depression in cognitively intact and/or younger populations, and may be less responsive to established interventions. In mild cognitive impairment, depressive symptoms are associated with higher rates of progression to dementia, and may identify a subset of individuals that are more responsive to acetylcholinesterase inhibitor treatment. Clinical and subsyndromal depressive symptoms in cognitively normal elderly individuals represent a risk factor and/or prodrome for dementia due to AD; however, sustained antidepressant therapy may be able to modulate this risk.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available